clinical trial · NCT04313504
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Trisha Wise-Draper·phase2·completed·n = 10
Head and Neck CancerNiraparibDostarlimab
brief summary
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
started
Nov 4, 2020
primary completion
Jun 1, 2025
completion
Mar 4, 2026
last updated
May 7, 2026
detailed description
Recurrent and/or metastatic HNSCC patients will be treated with combination of the PD-1 inhibitor (dostarlimab) and PARPi (niraparib) concurrently and ORR, PFS and OS will be determined.
official title
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol